Canadian Healthcare Technology Logo
  • Issues
    • Current Print Issue
    • Print Archive
  • Advertise
    • Publishing Schedule
    • Circulation
    • Unit Sizes and Rates
    • Mechanical Requirements
    • Electronic Advertising
    • White Papers
  • Subscribe
    • Print Edition
    • e-Messenger
    • White Papers
  • Events
  • Vendors
  • About Us

GE [April2023]

GE [April2023]

Enovacom EPC

Enovacom EPC

Clinical Solutions

Solution makes use of IBM cloud to spot pandemics

December 6, 2017


Mohammad QadirVANCOUVER – IBM announced that Vancouver-based company Fusion Genomics has selected IBM’s cloud capabilities to help advance Fusion’s ability to detect pandemics before they happen. Fusion Genomics has developed disruptive DNA and RNA technology that it believes can positively identify infectious diseases and enhance the surveillance of emerging pathogens like MERS, SARS, avian flu, and swine flu.

According to Fusion, Fusion Genomics’ technology when employed for pre-emergence surveillance can help proactively identify threats, like swine flu, by taking aerosol samples in high risk areas, then analyze the sample to determine if there is potential to affect humans.

If there is a risk, Fusion Genomics can help groups like governments and hospitals make rapid and informed decisions for the health and safety of those that rely on them before an outbreak occurs.

Requiring a cloud platform tuned for machine learning workloads, which also provides secure infrastructure capable of hosting sensitive genomic data, Fusion Genomics determined that the IBM Cloud was the ideal solution. The global infrastructure footprint of the IBM Cloud helps Fusion Genomics create a more coordinated and efficient delivery system that can scale up or down as needed. In addition, IBM Cloud positioned the company to analyze genomic data in minutes.

The IBM Cloud enables Fusion Genomics’ system to gather and process four core elements in unison:

• Beginning with testing, the sample genome is captured and DNA sequenced.

• Fusion Genomics’ machine learning algorithms then analyze the genomic data to identify the presence of a pathogen, including any forms that could cause public harm.

• Once identified, physicians using Fusion Genomics’ technology can provide appropriate therapeutics; thus, treatment can be determined while tracking the transmission dynamics of the pathogen.

• Since the system is delivered via the IBM Cloud, Fusion Genomics can easily run analytics and share information across boundaries.

“With a quickly growing global population, potential outbreaks of infectious diseases pose an increasingly pressing threat to our public health,” said Mohammad Qadir (pictured), president of Fusion Genomics. “We chose IBM over other cloud providers because of its ability to quickly scale up or down while ensuring that sensitive data is protected with one of the most secure clouds available. This accelerates our capacity to react to infectious diseases that can pose dangerous threats to both the economy and human life.”

“Together with Fusion Genomics, IBM continues its commitment to drive innovation in Canada that is making a real difference in key industries,” said Allen Lalonde, IBM Canada’s senior innovation executive with the IBM Canada Research & Development Centre. “IBM Cloud is designed to help meet the evolving needs of all scopes of businesses and technology challenges and can deliver a security minded end-to-end system that provides an environment, data governance, auditability, and interfaces for health data standards and systems.”

Organizations around the world are working with Fusion Genomics to access their DNA and RNA technology system built on IBM Cloud, including government agencies in both Canada and the European Union.

IBM Cloud offers a growing catalogue of services including AI, Internet of Things, analytics, blockchain, serverless and more. With nearly 60 cloud data centres in 19 countries worldwide, IBM is helping companies manage and gain insight from their data when and where they need it.

For more information about IBM Cloud, please visit https://www.ibm.com/cloud-computing/

About Fusion Genomics

Fusion Genomics in Vancouver BC, is developing Advanced Molecular Diagnostics tests for pathogens using their proprietary technologies in combination with Next Generation Sequencing. Their ONETest, in combination with FUSIONCloud, their data analysis platform, is designed to identify accurately, rapidly and economically, the genetic signatures of all known pathogens. FUSION Genomics ONETest is currently being tested at various key opinion leaders in Canada and the European Union.

PreviousNext

CHT print [900×150]

CHT print [900x150]

News and Trends

  • Ottawa’s health information demands will benefit patients
  • AI-powered tool on St. Michael’s surgical unit helps to improve care
  • Bots to help doctors reduce time spent on electronic records
  • Bissell Centre uses analytics to better understand client data
  • Canadian team is making ultrasound easier to use
More from the Print Edition

Subscribe

Subscribe

Free of charge to Canadian hospital managers and executives in nursing homes and home-care organizations. Learn More

Follow us on Social Media!

Follow us on Social Media!

Softworks

Softworks

Cdn Institute HCIwest

Cdn Institute HCIwest

Nihi Spring 2023

Nihi Spring 2023

Advertise with us

Advertise with us

Sectra [Feb]

Sectra [Feb]

Change Healthcare [2]

Change Healthcare [2]

Infoway [April2023]

Infoway [April2023]

Zebra [Mar2023]

Zebra [Mar2023]

RealTime

RealTime

CHT print [900×150]

CHT print [900x150]

Advertise with us

Advertise with us

Sectra [Feb]

Sectra [Feb]

Change Healthcare [2]

Change Healthcare [2]

Infoway [April2023]

Infoway [April2023]

Zebra [Mar2023]

Zebra [Mar2023]

RealTime

RealTime

Contact Us

Canadian Healthcare Technology
1118 Centre Street, Suite 207
Thornhill, Ontario, Canada L4J 7R9
Tel: 905-709-2330
Fax: 905-709-2258
info2@canhealth.com

  • Quick Links
    • Current Print Issue
    • Print Archive
    • Events
    • Vendors
    • About Us
  • Advertise
    • Publishing Schedule
    • Circulation
    • Unit Sizes and Rates
    • Mechanical Requirements
    • Electronic Advertising
    • White Papers
  • Subscribe
    • Print Edition
    • e-Messenger
    • White Papers
  • Resources
    • White Papers
    • Writers’ Guidelines
    • Privacy Policy
  • Topics
    • Administrative Solutions
    • Clinical Solutions
    • Companies
    • Continuing Care
    • Diagnostics
    • Education & Training
  •  
    • Electronic Records
    • Government & Policy
    • Infrastructure
    • Innovation
    • People
    • Privacy and Security

© 2023 Canadian Healthcare Technology

The content of Canadian Healthcare Technology is subject to copyright. Reproduction in whole or in part without prior written permission is strictly prohibited. Send all requests for permission to Jerry Zeidenberg, Publisher.

Search Site

Error: Enter a search term

  • Issues
    • Current Print Issue
    • Print Archive
  • Advertise
    • Publishing Schedule
    • Circulation
    • Unit Sizes and Rates
    • Mechanical Requirements
    • Electronic Advertising
    • White Papers
  • Subscribe
    • Print Edition
    • e-Messenger
    • White Papers
  • Events
  • Vendors
  • About Us